edgen-logo

AI Copilot
portfolioPortfolio

Stocks

Crypto

News
StocksCrypto

Chat History

Aura
Follow our

Join our

EN
Back

Syndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress
Stock NewsThemesSyndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress

Syndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress

Edgen StockEdgen Stock·Sep 13 2025, 22:02
Share to
Share to
Copy link
SNDXSNDX+2.38%
Syndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress
source:
[1] Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC (https://seekingalpha.com/article/4821782-synd ...)[2] Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update (https://vertexaisearch.cloud.google.com/groun ...)[3] Stifel resumes Syndax Pharmaceuticals stock coverage with Buy rating - Investing.com (https://vertexaisearch.cloud.google.com/groun ...)

Related News

Babcock & Wilcox Secures $40M Refinery Contract
Dec 19 2025, 22:38

Babcock & Wilcox Secures $40M Refinery Contract

Babcock & Wilcox announced on December 19, 2025, that it secured a $40 million contract to supply its Wet Gas Scrubbing technology to a Canadian petroleum refinery, major Canadian petroleum refinery.

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales
Dec 19 2025, 22:29

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales

A Yale study finds Elon Musk's political stance cost Tesla 1.26 million car sales, contributing to a profit drop to $7.1 billion in 2024 from $15 billion in 2023.

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes
Dec 19 2025, 22:27

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes

On December 16, Mizuho increased its price target for Tesla to $530, citing growing confidence in the automaker's future robotaxi business.